E. Sbidian, C. Hotz, . Chosidow, . Maruani, . Amelot et al., emilie.sbidian@aphp.fr Funding sources : none Conflict of interest statement

G. Jemec, Hidradenitis Suppurativa, New England Journal of Medicine, vol.366, issue.2, pp.158-64, 2012.
DOI : 10.1056/NEJMcp1014163

J. Revuz, F. Canoui-poitrine, and P. Wolkenstein, Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies, Journal of the American Academy of Dermatology, vol.59, issue.4, pp.596-601, 2008.
DOI : 10.1016/j.jaad.2008.06.020

C. Zouboulis, N. Desai, and L. Emtestam, European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa, Journal of the European Academy of Dermatology and Venereology, vol.36, issue.Suppl. 1, 2015.
DOI : 10.1111/jdv.12966

I. Miller, C. Lynggaard, and S. Lophaven, A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa, British Journal of Dermatology, vol.121, issue.2, pp.391-399, 2011.
DOI : 10.1111/j.1365-2133.2011.10339.x

A. Kimball, F. Kerdel, and D. Adams, Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa, Annals of Internal Medicine, vol.157, issue.12, pp.846-55, 2012.
DOI : 10.7326/0003-4819-157-12-201212180-00004

E. Sotiriou, C. Goussi, and A. Lallas, A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa, J Drugs Dermatol, vol.11, pp.15-20, 2012.

A. Grant, T. Gonzalez, and M. Montgomery, Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial, Journal of the American Academy of Dermatology, vol.62, issue.2, pp.205-222, 2010.
DOI : 10.1016/j.jaad.2009.06.050

D. Adams, J. Yankura, and A. Fogelberg, Treatment of Hidradenitis Suppurativa With Etanercept Injection, Archives of Dermatology, vol.146, issue.5, pp.501-505, 2010.
DOI : 10.1001/archdermatol.2010.72

F. Canoui-poitrine, L. Thuaut, A. Revuz, and J. , Identification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study, Journal of Investigative Dermatology, vol.133, issue.6, pp.1506-1517, 2013.
DOI : 10.1038/jid.2012.472

G. Martin-ezquerra, E. Masferrer, and M. Masferrer-niubo, Use of biological treatments in patients with hidradenitis suppurativa, Journal of the European Academy of Dermatology and Venereology, vol.24, issue.Suppl 2, pp.56-60, 2015.
DOI : 10.1111/jdv.12438

K. Hyrich, K. Watson, and A. Silman, Predictors of response to anti-TNF-?? therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register, Rheumatology, vol.45, issue.12, pp.1558-65, 2006.
DOI : 10.1093/rheumatology/kel149

F. Canoui-poitrine, J. Revuz, P. Wolkenstein, C. Viallette, G. Gabison et al., Bastuji-Garin S Smoking and hidradenitis suppurativa: risk or pronostic factor ? Results from a series of 947 patients, J Invest Dermatol, vol.132, pp.70-74, 2012.

B. Sicilia, F. Arribas, and J. Nerin, Risk factors for ulcerative colitis: A population-based, case???control study in Spain, Journal of Crohn's and Colitis, vol.2, issue.2, pp.158-61, 2008.
DOI : 10.1016/j.crohns.2008.01.003

A. European-medicines, First medicine recommended for approval for hidradenitis suppurativa. On september, 2015.